top of page
  • Active, not recruiting

NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma

Updated: Feb 10

  • NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

  • Dara Ixa Dex

  • Dara Vel Dex


dara-ixa-dex

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)



This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.



Sponsor:

Emory University


Collaborators:

Takeda

Janssen, LP


Location:

United States, Georgia

 

ClinicalTrials.gov Identifier: NCT03942224


Official Title: A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, Bortezomib (VElcade) and Dexamethasone Followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE Study)


First Posted : May 8, 2019


Click here for details on ClinicalTrials.gov

 



 

Drug: Bortezomib

Biological: Daratumumab

Drug: Dexamethasone

Drug: Ixazomib










Comments


Commenting has been turned off.
Posts Archive
bottom of page